Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In111-Pentetreotide in Resected Digestive Neuroendocrine Tumors
NCT02465112Phase 3Terminated
- Sponsor
- GERCOR
- Start
- Sep 2015
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of indium-111 pentetreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by GERCOR. Started Sep 2015; status: terminated.
02
Drugs
indium-111 pentetreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02465112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465112.